

of the spätzle ligand for the *Drosophila* Toll receptor that is generated via a serine protease cascade (24). In mature flies, Toll also functions in immunity to fungal pathogens, and derepression of this pathway, due to the absence of the Spn43Ac protease inhibitor, also results in necrosis (25).

Generating a mature ligand is unlikely to be the sole function of Rcr3, because *rcr3* mutants do not exhibit an HR when infiltrated with intercellular fluid preparations that contain Avr2 isolated from infected tomato plants (2).

Alternatively, Rcr3 could process Cf-2 or another plant protein. Differences in the substrate specificity or activity of Rcr3^{pim} and Rcr3^{esc} might explain why Rcr3^{esc} induces Avr2-independent necrosis. An extracellular protease is also required for brassinosteroid perception in *Arabidopsis* (26). Overexpression of the serine carboxypeptidase BRS1 suppresses extracellular domain mutants of the BRI1 LRR-receptor kinase. BRS1 may process a protein that forms part of the BRI1 ligand (26). Alternatively, Rcr3 might be a plant defense component that is inhibited by Avr2. Avr2 could also inhibit other cysteine proteases, either by binding to or by modifying them. Whether Rcr3 has a role in defense is not established. The Cf2 Rcr3 mutant lines do not appear more susceptible to *C. fulvum* than Cf0, but tomato encodes many different cysteine proteases. It is interesting that the *C. fulvum* Avr9 protein shows significant structural homology to several protease inhibitors (27).

It is possible that Avr2 and Rcr3 together constitute a complex ligand that is recognized by Cf-2. It has been suggested that R proteins act as 'guards' for specific proteins targeted by pathogen Avr proteins during infection (1, 2). Cf-2 may guard Rcr3 and trigger a defense response upon perception of an Rcr3/Avr2 complex. In *rcr3* mutants, no Avr2-independent signaling would occur either because no Rcr3^{pim}/Cf-2 complex is formed or because the complex does not activate defense signaling. A subtle structural difference in Rcr3^{esc} (Fig. 1A) may result in activation of an Avr2-independent response upon binding to Cf-2.

With the recent isolation of the Avr2 gene (28), it will be possible to determine whether the Avr2, Rcr3, and Cf-2 proteins can interact. This should further increase our understanding of the molecular mechanism of ligand perception by this unique class of R proteins.

References and Notes

1. J. L. Dangl, J. D. G. Jones, *Nature* **411**, 826 (2001).
2. M. S. Dixon, C. Golstein, C. M. Thomas, E. A. van der Biezen, J. D. G. Jones, *Proc. Natl. Acad. Sci. U.S.A.* **97**, 8807 (2000).
3. M. H. A. J. Joosten, P. J. G. M. de Wit, *Annu. Rev. Phytopathol.* **37**, 335 (1999).
4. T. Romeis, A. Ludwig, R. Martin, J. D. G. Jones, *EMBO J.* **20**, 5556 (2001).

5. M. S. Dixon, K. Hatzixanthos, D. A. Jones, K. Harrison, J. D. G. Jones, *Plant Cell* **10**, 1915 (1998).
6. Details of *Rcr3* cloning and characterization are available on Science online at www.sciencemag.org/cgi/content/full/296/5568/744/DC1. The GenBank accession numbers for *Rcr3*^{pim}, *Rcr3*^{esc}, and *Rcr3*^{pen} (from *L. pennellii*) are AF493232, AF493234, and AF493233, respectively.
7. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
8. P. J. G. M. de Wit, M. B. Buurlage, K. E. Hammond, *Physiol. Mol. Plant Pathol.* **29**, 159 (1986).
9. A. N. Langford, *Can. J. Res. (C)* **26**, 35 (1948).
10. Clone p2BL2 contains *Rcr3*^{esc}, expressed from its native promoter, from the *L. esculentum* cultivar Mogeor.
11. S. Tang, thesis, University of East Anglia (1998).
12. To determine whether *Cf-2/9* and *pCf-9:Cf-2* required *Rcr3* for resistance to *C. fulvum*, transgenic plants were crossed to Cf2 *Rcr3-2*. Kanamycin-resistant F₂ seedlings segregated 3:1 for resistance to *C. fulvum* race 5.
13. M. S. Dixon et al., *Cell* **84**, 451 (1996).
14. To determine whether autonecrosis is *Rcr3*^{esc}-dependent, a *pCf-9:Cf-2* transgenic line was intercrossed with the Cf2 *rcr3-2* line. Kanamycin-resistant F₂ progeny segregated 19 autonecrotic to 5 wild type ($\chi^2 = 0.22$ for a 3:1 ratio). Sequence analysis of asymptomatic plants revealed they were homozygous for the *rcr3-2* mutant allele.
15. *Cf-9* clones were five times more abundant in a cDNA library made from a Cf2/Cf9 line.
16. M. R. Groves et al., *Structure* **4**, 1193 (1996).
17. Details of *Rcr3* epitope tagging and transient expression are available on Science Online at www.sciencemag.org/cgi/content/full/296/5568/744/DC1. Various tags for immunodetection were used, including His, His-HA, and HA.
18. To control for protein in the intercellular fluid originating from broken cells, a Western blot was probed with antibodies against AtPhos43, a cytoplasmic *A. thaliana* protein [S. Peck et al., *Plant Cell* **13**, 1467 (2001)].
19. D. Michaud, L. Faye, S. Yelle, *Electrophoresis* **14**, 94 (1993).
20. A. Minami, H. Fukuda, *Plant Cell Physiol.* **36**, 1599 (1995).
21. M. Solomon, B. Belenghi, M. Delledonne, E. Mennachem, A. Levine, *Plant Cell* **11**, 431 (1999).
22. M. Estelle, *Curr. Opin. Plant Biol.* **4**, 254 (2001).
23. T. Pechan et al., *Plant Cell* **12**, 1031 (2000).
24. E. K. LeMosy, Y.-Q. Tan, C. Hashimoto, *Proc. Natl. Acad. Sci. U.S.A.* **98**, 5055 (2001).
25. E. A. Levashina et al., *Science* **285**, 1917 (1999).
26. J. Li, K. A. Lease, F. E. Tax, J. C. Walker, *Proc. Natl. Acad. Sci. U.S.A.* **98**, 5916 (2001).
27. J. Vervoort et al., *FEBS Lett.* **404**, 153 (1997).
28. R. Luderer, F. L. W. Takken, P. J. G. M. de Wit, M. H. A. J. Joosten, in preparation.
29. We thank members of the Jones' laboratory and C. Dean for useful discussions, S. Perkins and J. Campling for horticultural service, M. Weaver for binary vector plasmids, O. Voinnet and D. Baulcombe for viral anti-silencing vectors and S. Peck and F. Meins for AtPhos43 antibody. J.K. was supported by an EMBO long-term fellowship. M.D. was supported by Biotechnology and Biological Sciences Research Council grant 208/A06586. The Sainsbury Laboratory is supported by the Gatsby Charitable Foundation.

21 December 2001; accepted 18 March 2002

A Role for Skin $\gamma\delta$ T Cells in Wound Repair

Julie Jameson,¹ Karen Ugarte,¹ Nicole Chen,¹ Pia Yachi,¹ Elaine Fuchs,² Richard Boismenu,¹ Wendy L. Havran^{1*}

$\gamma\delta$ T cell receptor-bearing dendritic epidermal T cells (DETCs) found in murine skin recognize antigen expressed by damaged or stressed keratinocytes. Activated DETCs produce keratinocyte growth factors (KGFs) and chemokines, raising the possibility that DETCs play a role in tissue repair. We performed wound healing studies and found defects in keratinocyte proliferation and tissue reepithelialization in the absence of wild-type DETCs. In vitro skin organ culture studies demonstrated that adding DETCs or recombinant KGF restored normal wound healing in $\gamma\delta$ DETC-deficient skin. We propose that DETCs recognize antigen expressed by injured keratinocytes and produce factors that directly affect wound repair.

$\gamma\delta$ T cells compose a major T cell component in epithelial tissues (1, 2). The tight correlation between T cell receptor (TCR) V gene segment usage and tissue localization suggests a highly specialized function. $\gamma\delta$ TCR-bearing DETCs found in murine skin produce cytokines and proliferate in response to damaged or stressed keratinocytes (3), indicating a functional inter-

action between these two neighboring cell types in vivo. DETCs produce KGF-1, also called fibroblast growth factor-7 (FGF-7), following stimulation through the $\gamma\delta$ TCR (4). Both FGF-7 and KGF-2 (FGF-10) bind the FGFR2-IIIb receptor and have been implicated in wound healing (5–15). To directly test the potential role of $\gamma\delta$ T cells in wound repair, we set up wound healing studies in mice lacking $\gamma\delta$ DETCs.

Location, morphology, and density of DETCs were evaluated after wounding of C57BL/6 mouse ear skin (16) (Fig. 1, A through C). Twenty-four to 48 hours after full-thickness wounding, DETCs located around the wound exhibited a change in morphology characterized

¹Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA. ²Department of Molecular Genetics and Cell Biology, Howard Hughes Medical Institute, The University of Chicago, Chicago, IL 60637, USA.

*To whom correspondence should be addressed. E-mail: havran@scripps.edu

Fig. 1. $\gamma\delta$ DETCs participate in wound repair. (A through C) Detection of DETCs in epidermal sheets isolated from C57BL/6 (B6) mice with a $\gamma\delta$ TCR-specific mAb (PE-GL3; Pharmingen, La Jolla, CA) (16, 27, 28). Arrows indicate the wound edge. (A) Nonwounded (magnification $\times 200$). Day 2 after wounding (B) $\times 200$ and (C) $\times 100$. Data are representative of wounds examined from at least 10 mice. (D) Photographic images of excision wounds from B6 and TCR $\delta^{-/-}$ mice 2 days after wounding. (E) Wound closure kinetics in wild-type ($\blacktriangle$) and TCR $\delta^{-/-}$ mice ($\circ$). Data are representative of at least three experiments. $^{**}p < 0.005$ and $^{*}p < 0.05$ using an unpaired 2-tailed Student *t*-test.





Fig. 2. $\gamma\delta$ DETCs affect epidermal thickening and keratinocyte proliferation in wounded tissue. Detection of proliferating cells in wounded tissue by BrdU labeling in wild-type (A and C) and TCR $\delta^{-/-}$ (B and D) mice 3 days after wounding (16). Wound edge is marked with arrow ($\downarrow$) (A and B) $\times 100$ and (C and D) $\times 200$ magnification. Representative BrdU-positive cells are marked by arrows; e, epidermis; h, hair follicles; and Es, eschar. (E) Quantification of BrdU-positive cells in B6 ($\blacktriangle$) and TCR $\delta^{-/-}$ ($\circ$) skin. At each time point, BrdU-positive cells were quantified from at least six individual mice per strain (16). (F) BrdU incorporation at the wound site 5 days after wounding in wild-type, TCR $\delta^{-/-}$, OT-1 Rag $^{-/-}$, and Rag $^{-/-}$ mice. No significant differences were observed between OT-1 Rag $^{-/-}$, Rag $^{-/-}$, and TCR $\delta^{-/-}$ mice. $^{**}p < 0.005$ and $^{*}p < 0.01$ using an unpaired 2-tailed Student *t*-test compared to B6 mice.



wound retained their normal shape.


To determine whether DETCs participate in wound repair, wild-type and TCR $\delta^{-/-}$ mice received full-thickness wounds in their back skin (16), and the rate of wound closure was assessed over a 20-day period. Clear differences in wound size and rate of healing were evident when wild-type and TCR $\delta^{-/-}$ wounds were compared on each day after wounding, as shown for day 2 (Fig. 1D). TCR $\delta^{-/-}$ mice had a 2- to 3-day delay in wound closure relative to wild-type mice (Fig. 1E). Histological analysis of full-thickness wounds revealed reduced epithelial hyperthickening in the TCR $\delta^{-/-}$ mice, relative to wild-type mice (Fig. 2, A through D), suggesting that keratinocyte proliferation was impaired in the absence of $\gamma\delta$ DETC. To test this more directly, we injected mice with BrdU at various times after wounding (16). Significantly fewer BrdU-positive epidermal cells were detected from the wound edge to the wound center in TCR $\delta^{-/-}$ compared to wild-type mice (Fig. 2, C through E). Together, these data indicate that $\gamma\delta$ T cells play a role in keratinocyte proliferation and reepithelialization during wound healing.

DETCs are activated through the canonical V γ 3V δ 1 TCR by antigen expressed by stressed keratinocytes. Mice that lack the canonical V γ 3 chain have DETCs with a TCR that retains the original V γ 3 conformation and antigen specificity (18), emphasizing the functional relevance of this TCR. To determine if DETC activation in response to wounding requires V γ 3V δ 1, we utilized OT-1 TCR transgenic mice (19) on a Rag $^{-/-}$ background. In OT-1 mice, all T cells, including DETCs, express an identical V α 2V β 5 TCR that recognizes an ovalbumin peptide complexed with I-A^b (19). BrdU incorporation in the wound was diminished (Fig. 2F) and wound closure delayed (17) in OT-1 compared to wild-type mice in a manner similar to that observed in TCR $\delta^{-/-}$ mice.

by a partial loss of the distinctive dendritic shape, although no significant change in DETC density was observed (Fig. 1, B and C). Five

days after wounding, the DETCs at the wound margins began to regain their dendritic morphology (17). DETCs that were distant from the

Fig. 3. FGF-7 and FGF-10 mediate the DETC response to wounding. Levels of (A) FGF-7 and (B) FGF-10 mRNA isolated from purified DETCs from nonwounded (C) or day-2-wounded (W) B6 mice, or positive control DETC cell line (7-17) (16, 29). Addition of FGF-7 or DETCs to wounds from TCR $\delta^{-/-}$ mice in skin organ culture (24, 25) restores wound closure and keratinocyte proliferation to wild-type levels. In each experiment, three to four wounds were measured over time for each strain of mouse and culture condition (16). (C) Wound closure kinetics in wounded B6 skin ($\blacktriangle$), TCR $\delta^{-/-}$ skin ($\circ$) and TCR $\delta^{-/-}$ skin plus FGF-7 (50 μ g/ml) ($\bullet$). BrdU incorporation at the wound site in the presence of (D) FGF-7 (50 μ g/ml) or (E) Con A-activated 7-17 cells. $**p < 0.001$ using an unpaired 2-tailed Student *t*-test. Results in (A) through (E) are representative of two to three experiments.



We conclude that DETCs contribute to wound repair via specific recognition of antigen mediated through the V γ 3V δ 1 TCR.

$\gamma\delta$ DETCs do not constitutively produce FGF-7 but require activation through the TCR (4). Furthermore, keratinocyte proliferation mediated by $\gamma\delta$ DETCs was inhibited by a FGFR2-IIIb neutralizing peptide (20), indicating that KGFs are the major epithelial growth factors produced by DETCs (4). To determine if $\gamma\delta$ DETCs are activated to produce FGF-7 in response to tissue injury, FGF-7 expression was examined in full-thickness wounds (16) (Fig. 3A). FGF-7 mRNA was detected in DETCs isolated from the wound area but not from nonwounded skin. In addition, mRNA encoding other factors including TNF- α and IFN- γ was expressed by DETCs following wounding (17). The data suggest that DETCs in wounded skin are activated by neighboring, damaged keratinocytes and play a role in wound repair by expressing KGFs and cytokines.

Because no significant wound healing defect has been observed in FGF-7 $^{-/-}$ mice (15, 21), we examined whether $\gamma\delta$ DETCs also produced FGF-10. The importance of FGF-10 in wound healing cannot be studied in FGF-10 $^{-/-}$ mice as they die shortly after birth (22, 23). Because the DETC cell line 7-17 produced FGF-10 upon TCR stimulation, it was possible that DETCs might participate in wound healing by production of FGF-10. Consistent with this, FGF-10 was detected in wounded skin obtained from

wild-type and FGF-7 $^{-/-}$ mice, but not in the epidermis of wounded TCR $\delta^{-/-}$ mice, indicating that DETCs were the key source of FGF-10 in the wounded epidermis 2 days after wounding (Fig. 3B).

A skin organ culture (SOC) assay was used to further characterize the contribution of $\gamma\delta$ DETC-produced factors to wound repair and keratinocyte proliferation (16, 24, 25). The in vivo finding that TCR $\delta^{-/-}$ mouse skin showed delayed kinetics of wound closure when compared with wild-type mouse skin could be reproduced in the SOC assay (Fig. 3C). Significantly, addition of FGF-7 normalized the wound closure rate and BrdU incorporation observed with TCR $\delta^{-/-}$ skin (Fig. 3D). Skin from OT-1 Rag $^{-/-}$ and Rag $^{-/-}$ mice exhibited similar delays in wound closure as TCR $\delta^{-/-}$ skin in SOC (22). Addition of Con A-activated 7-17 cells to the culture of wounded TCR $\delta^{-/-}$ skin restored proliferation to wild-type levels (Fig. 3E). Together, these data indicate that the defect in keratinocyte proliferation and wound closure in TCR $\delta^{-/-}$ mice can be attributed to a lack of KGFs produced by DETCs.

Wound healing is a complex process that involves epithelial cell proliferation, granulation tissue deposition, and inflammatory cell recruitment. Many cell types are involved in this process; however, the role of resident DETCs in wound repair has been neglected. Here, we demonstrate that mice lacking DETCs have a significant delay in wound healing and impaired epidermal cell prolifer-

ation. We have proposed that DETCs recognize antigen expressed on neighboring epithelial cells following injury or disease (3), and participate in tissue repair through the local production of factors including FGF-7 and FGF-10. DETCs are considered a prototype intraepithelial $\gamma\delta$ T cell population, raising the possibility that participation in tissue repair is a conserved function shared by intraepithelial $\gamma\delta$ T cells in different epithelial tissues. Indeed, we have recently shown that intestinal intraepithelial $\gamma\delta$ T cells protect the intestinal mucosa from damage (26). Future studies of epithelial diseases such as inflammatory bowel disease, asthma, and wound healing will need to consider the role of intraepithelial $\gamma\delta$ T cells in disease progression and tissue repair as well as in design of treatment strategies.

References and Notes

1. J. P. Allison, W. L. Havran, *Annu. Rev. Immunol.* **9**, 679 (1991).
2. A. C. Hayday, *Annu. Rev. Immunol.* **18**, 975 (2000).
3. W. L. Havran, Y.-H. Chien, J. P. Allison, *Science* **252**, 1430 (1991).
4. R. Boismenu, W. L. Havran, *Science* **266**, 1253 (1994).
5. J. S. Rubin et al., *Proc. Natl. Acad. Sci. U.S.A.* **86**, 802 (1989).
6. P. W. Finch, J. S. Rubin, T. Miki, D. Ron, S. A. Aaronson, *Science* **245**, 752 (1989).
7. S. Werner et al., *Proc. Natl. Acad. Sci. U.S.A.* **89**, 6896 (1992).
8. S. Werner et al., *Science* **266**, 819 (1994).
9. L. Staiano-Coico et al., *J. Exp. Med.* **178**, 865 (1993).
10. M. Yamasaki, A. Miyake, S. Tagashira, N. Itoh, *J. Biol. Chem.* **271**, 15918 (1996).
11. H. D. Beer et al., *Oncogene* **15**, 2211 (1997).
12. S. Tagashira, H. Harada, T. Katsumata, N. Itoh, M. Nakatsuka, *Gene* **197**, 399 (1997).
13. Y. P. Xia et al., *J. Pathol.* **188**, 431 (1999).
14. P. A. Jimenez, M. A. Rampy, *J. Surg. Res.* **81**, 238 (1999).
15. S. Werner, *Cytokine Growth Factor Rev.* **9**, 153 (1998).
16. Supplementary details of experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/296/5568/747/DC1.
17. J. M. Jameson et al., unpublished observations.
18. C. A. Mallick-Wood et al., *Science* **279**, 1729 (1998).
19. K. A. Hogquist et al., *Cell* **76**, 17 (1994).
20. D. P. Bottaro, E. Fortney, J. S. Rubin, S. A. Aaronson, *J. Biol. Chem.* **268**, 9180 (1993).
21. L. Guo, L. Degenstein, E. Fuchs, *Genes Dev.* **10**, 165 (1996).
22. H. Min et al., *Genes Dev.* **12**, 3156 (1998).
23. K. Sekine et al., *Nature Genet.* **21**, 138 (1999).
24. P. Jaakkola, S. Kontusaari, T. Kauppi, A. Maata, M. Jalkanen, *FASEB J.* **12**, 959 (1998).
25. S. Sakai, R. Yasuda, T. Sayo, O. Ishikawa, S. Inoue, *J. Invest. Dermatol.* **114**, 1184 (2000).
26. Y. Chen, K. Chou, E. Fuchs, W. Havran, R. Boismenu, *Proc. Natl. Acad. Sci. U.S.A.*, in press.
27. P. R. Bergstresser, R. E. Tigelaar, J. H. Dees, J. W. Streilein, *J. Invest. Dermatol.* **81**, 286 (1983).
28. E. Tschachler et al., *J. Invest. Dermatol.* **81**, 282 (1983).
29. W. L. Havran et al., *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4185 (1989).
30. We thank S. Werner for providing FGF-10 advice and reagents, C. Surh for OT-1 Rag $^{-/-}$ mice, and Amgen for recombinant FGF-7. We also thank H. Gardner, Y. Chen, D. Schlaepfer, D. Witherden, S. Rieder, and L. Teyton for advice and review of the manuscript. This work was supported by NIH grants AI36964 and AI32751 (W.L.H.) and 5T32 AI07244 (J.J.). W.L.H. is a Scholar of the Leukemia and Lymphoma Society. This is manuscript 14404-IMM from The Scripps Research Institute.

8 January 2002; accepted 19 March 2002